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Mast cells (MCs) are known to be regulators of inflammation and immunity, due to 
the released mediators and expressed cell surface molecules. 
Lupus erythematosus (LE) is a group of diseases which can be systemic or limited to 
the skin. Due to the fact that cytokines and chemokines produced by inflammatory 
cells contribute to the pathogenesis of LE, we quantified the number of mast cells 
present in the skin.
The aim of the study was to compare the chymase-positive and tryptase-positive 
mast cell counts within skin biopsies from patients with systemic lupus erythe-
matosus (SLE), discoid lupus erythematosus (DLE) and subacute cutaneous lupus 
erythematosus (SCLE).
The material consisted of 45 skin biopsies: 6 with SLE, 34 with DLE and 5 with 
SCLE. Chymase- and tryptase-positive cells were stained by immunohistochemis-
try and counted. 
The mean count of chymase-positive mast cells was 85.14 hpf for the whole group, 
35.83 for SLE, 88.48 for DLE and 121.6 for SCLE. The mean count of trypt-
ase-positive cells was 120.05 hpf for the entire group, 59.17 for SLE, 126.42 for 
DLE and 149.8 for SCLE. The differences between groups were significant for 
chymase- and tryptase-positive cells.
Key words: systemic lupus erythematosus, discoid lupus erythematosus, SLE, DLE, 
mast cell, chymase, tryptase.
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Introduction
Mast cells (MCs) are bone-marrow derived cells 
well known for their contribution to allergic reac-
tions. They also play an important role in innate and 
adaptive immune responses [1]. Mast cells reside in 
vascularized tissues, i.e. in the intestinal mucosa and 
in the skin. In normal conditions they are found in 
subcutaneous fat and dermis, near blood vessels, hair 
follicles and nerves [2, 3]. They contain granules with 
a vast array of mediators, i.e. histamine, heparin, chy-
mase, tryptase, etc. [1, 3]. In the innate response, 
they can both detect the pathogens and release prop-
er mediators to promote a pathogen-specific clear-
ance mechanism. They play an important role in 
the protection against bacteria, viruses and parasites 
[1, 4]. In adaptive immunity they interact with T hel- 
per (Th) and T regulatory (Treg) cells, mainly stim-
ulating T effector cells and suppressing Tregs [1, 5].
Initially, human mast cells were divided into two 
subtypes: chymase-positive, containing both chymase 
and tryptase (MCTC), and tryptase-positive (MCT), con-
taining only tryptase [6, 7]. However, there is a claim 
that a third subset – only chymase-positive mast cells 
(MCC) – exists [8] or even there is a wider spectrum 
of MCs subgroups, varying in the number and types 
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of mediators they produce when activated [3]. In the 
skin, the MCTC population predominates [9].
Chymase and tryptase are multifunctional serine 
proteases playing a role inter alia in wound healing 
by promoting fibroblast proliferation and metal-
loproteinase activation. Chymase induces vascular 
permeability and collagen remodeling. Tryptase, cre-
ating a complex with heparin, degrades fibrinogen 
in the wound healing process to prevent its further 
accumulation and thrombus formation. It regulates 
granulocyte and/or macrophage accumulation in tis-
sues [3]. However, these two proteases have the abil-
ity to degrade many protein and peptides, which can 
lead to skin damage [10]. Also, MCs are suspected to 
participate in skin inflammation in the course of lu-
pus erythematosus (LE), due to the metalloproteinase 
production and contribution to immune cell migra-
tion and tissue damage [11]. 
Lupus erythematosus can be divided into systemic 
and cutaneous forms. Systemic lupus erythematosus 
(SLE) is an autoimmune disorder affecting multiple 
organs: lungs, brain, heart, kidney and skin. It is char-
acterized by the loss of tolerance for self antigens and 
production of auto-antibodies. Formed immune com-
plexes trigger the complement cascade, resulting in 
inflammation and tissue damage [12]. The skin is the 
second most frequently involved organ in SLE [13].
Discoid lupus erythematosus (DLE) is a cutaneous 
form of lupus with a wide spectrum of manifestations 
[14]. Its name can be confusing, due to the fact that it 
may refer to a particular type of LE or to coin-shaped 
lesions occurring in the course of LE. Discoid lupus 
erythematosus is the most common type of LE, limit-
ed to the skin. It has a localized form in the head and 
neck area, or it can be disseminated (head, neck, limb 
and trunk). The disseminated form can transform into 
SLE. The other name for DLE, often used in publi-
cations, is cutaneous lupus erythematosus (CLE) [15].
Subacute cutaneous lupus erythematosus (SCLE) 
is a transitional type of LE, between DLE and SLE. 
It affects only some organs and is associated with UV 
hypersensitivity.
To distinguish the subtypes of LE there are some 
diagnostic criteria established: histological changes 
of skin biopsy and laboratory abnormalities [14, 16].
The aim of the study was to compare the counts 
of chymase-positive and tryptase-positive mast cells 
in the skin biopsies from patients with SLE, DLE and 
SCLE.
Material and methods
The material consisted of 45 skin biopsies: 6 from 
patients with SLE, 34 from patients with DLE, and 
5 from patients with SCLE. The biopsy area was not-
ed – face, hairy head or other (trunk, limb). Material 
was collected from the archives of the Department of 
Pathomorphology (Collegium Medicum, Jagiellonian 
University, Krakow).
All cases were examined by immunofluorescence 
for the presence of IgA, IgG, IgM, C3c and fibrino-
gen (the lupus band test) on frozen sections.
Afterwards, the material was fixed in formalin, 
processed by a routine method and embedded in par-
affin; 4 μm sections were cut from paraffin blocks and 
stained with standard hematoxylin and eosin, period-
ic acid–Schiff and Alcian blue methods.
The immunohistochemistry was done by a rou-
tine manual method. Primary anti-tryptase antibody 
(1 : 100; Leica Biosystems GmbH, Wetzlar, Germany) 
and anti-chymase antibody (1 : 100; Abcam, Cam-
bridge, UK) were used. The Lab Vision detection sys-
tem (Thermo Fisher Scientific, Waltham, MA, USA) 
was used with 3-amino-9-ethylcarbazole as the chro-
mogen. The slides were counterstained with Mayer’s 
hematoxylin (Thermo Fisher Scientific) and covers-
lipped. The immunostained slides were examined on 
an Olympus CH20 optical microscope equipped with 
a 40× lens; the number of immunopositive cells and 
number of fields of view were documented. The re-
sults were expressed as a sum of positive cells from 
10 high power fields (hpf), while the area of one hpf 
was 0.159 mm2. The person performing the assess-
ment was not aware of the diagnoses.
The statistical analysis was performed with Statis-
tica 10 (StatSoft Inc., Tulsa, OK, USA). Kruskal-Wal-
lis ANOVA was used; correlations were measured by 
Spearman’s correlation. The significance level was set 
at 0.05.
Results
Mean age of all patients was 44.53 ±11.5 years 
(all values expressed as arithmetic mean ± SD), 
range 22-66 years. For SLE the mean age was 47.5 
±17.84, for DLE 43.65 ±10.16 years and for SCLE 
47 ±13.3 years. Mean age for females was 45.59 
±12.06 years and 42.63 ±10.5 years for males. The 
differences between patients’ ages in groups were not 
statistically significant.
The mean count of chymase-positive mast cells 
(MCs) was 85.14 ±52.08 per 10 high power fields, 
while the mean count for tryptase-positive MCs was 
120.05 ±68.05. The average ratio of chymase-posi-
tive to tryptase-positive cell count was 0.73 ±0.29. 
In SLE the chymase-positive mast cell count was 
35.83 ±30.17 per 10 high power fields, while the 
mean count for tryptase-positive MCs was 59.17 
±40.94. The average ratio of chymase-positive to 
tryptase-positive cell count was 0.6 ±0.23. In DLE 
the chymase-positive mast cell count was 88.48 
±50.71 per 10 high power fields, while the mean 
count for tryptase-positive MCs was 126.42 ±69.01. 
The average ratio of chymase-positive to trypt-
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ase-positive cell count was 0.75 ±0.32. In SCLE the 
chymase-positive mast cell count was 121.6 ±45.64 
per 10 high power fields, while the mean count for 
tryptase-positive MCs was 149.8 ±50.5. The aver-
age ratio of chymase-positive to tryptase-positive cell 
count was 0.82 ±0.11.
The differences between groups in chymase-pos-
itive cell counts and tryptase-positive cells were 
statistically significant (p = 0.008 and p = 0.02, 
respectively). On post-hoc analysis differences in 
chymase-positive MC count were found between all 
three groups, SLE, DLE and SCLE, whereas in the 
tryptase-positive MC count a difference was found 
between SLE and SCLE. The differences in the ratio 
of chymase-positive to tryptase-positive cells between 
groups were not significant; however, there was a sig-
nificant correlation between the ratio of chymase-pos-
itive to tryptase-positive cells and chymase-positive 
cell count (R = 0.31). Chymase-positive MC counts 
and tryptase-positive MC counts were strongly cor-
related (R = 0.85). In SLE and DLE groups there 
was a strong correlation between chymase-positive 
MC count and tryptase-positive MC count (R = 0.89 
and R = 0.82, respectively). The highest mean count 
of chymase-positive and tryptase-positive mast cells 
was in the biopsies collected from the face (106.56 
±44.72, 142.66 ±67.08, respectively). It was lower 
in the biopsies collected from the hairy head (94.13 
±70.91, 135.56 ±83.55, respectively) and the low-
est in the biopsies collected from other places (74.43 
±44.35, 90.14 ±51.60, respectively). There was no 
statistically significant difference in the number of 
mast cells between the biopsy areas.
Discussion
Mast cells are the principal immune cells taking 
part in allergic reactions and playing an important 
role in innate and adaptive immunity [1]. In many 
organs, e.g. the kidney, they contribute to local in-
flammation and tissue remodeling [17, 18]. 
Mast cells are found in the skin in normal condi-
tions, but their number increases in chronic skin in-
flammation, e.g. psoriasis, and in some tumors such 
as basal cell carcinoma. They may be involved in the 
pathogenesis of these diseases due to the wide range 
of released mediators. Their activity is dual, both 
proinflammatory and immunosuppressive. Mast cells 
can recruit other immune cells such as T cells, eo-
sinophils and neutrophils, as well as activate Langer-
hans and dendritic cells. Two of their serine proteases 
– chymase and tryptase – contribute to these pro-
cesses. Tryptase activates endothelial cells, peripher-
al blood mononuclear cells, T cells and neutrophils, 
as well as metalloproteinases and pro-urokinase. It 
also degrades chemokines, neuropeptides and cathe-
licidin LL-37 acting as an inhibitor. Chymase also 
recruits immune cells and activates some pro-inter-
leukins. However, it degrades interleukin-6 and -15 
and to some extent IL-5 and tumor necrosis factor α 
(TNF-α) [9].
The pathogenesis of the cutaneous form of LE en-
compasses immunologic, environmental and genetic 
factors. Some of the genes encoding cytokines [in-
terleukin (IL)-1, IL-10], their receptors, apoptosis 
genes and adhesion molecules seem to increase the 
susceptibility to CLE, as well as inherited deficien-
cies of complement components. From the environ-
mental factors, the major trigger is UV light, which 
induces the release of proinflammatory factors such 
as TNF-α, IL-1, IL-6, etc., and apoptosis. However, 
other agents eliciting inflammation such as trauma, 
scratching, coldness or burns may contribute to LE 
development. In this disease, the tissue damage is 
caused by overlapping events such as impaired clear-
ance of apoptotic material, the presence of autoanti-
Fig. 1. Tryptase positive cells in skin, systemic lupus er-
ythematosus. Immunohistochemistry, original magnifica-
tion 400×
Fig. 2. Tryptase positive cells in skin, discoid lupus erythe-
matosus. Immunohistochemistry, original magnification 
400×
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bodies, activity of TNF-α and interferons (INFs), as 
well as disturbance of immune regulation due to the 
lower number of Tregs.
Recent studies have shown that CLE subsets share 
some similarities in their pathogenesis. However, 
they differ in particular points of the pathogenic 
mechanism, e.g. in the type of antinuclear antibodies 
binding to the antigens on the surface of keratino-
cytes [19, 20]. 
The clinical manifestation of the subtypes of cu-
taneous lupus varies. SCLE is characterized by sym-
metric distribution of lesions on sun-exposed areas 
presenting initially as erythematous macules or pap-
ules, transforming into scaly, papulosquamous or an-
nular/polycyclic plaques. The lesions can be triggered 
by UV light or drugs. Discoid lupus erythematosus 
presents as a localized form with lesions on the face, 
ears, and scalp or rarely as a disseminated type with 
lesions above and below the neck. Lesions appear in 
sun-exposed areas but also in palmoplantar sites. Most 
commonly it is characterized by scaling erythematous 
discoid plaques, leading with time to scarring. The in-
flammation in DLE mostly involves the bulge area of 
the follicles [16, 21].
To distinguish SLE from other diseases, the Amer-
ican College of Rheumatology (ACR) established cri-
teria including 11 clinical and laboratory features; 
4 of the 11 ACR criteria include mucocutaneous le-
sions (malar rash, discoid lesions, photosensitivity, 
and oral ulcers). In 2012, the Systemic Lupus Inter-
national Collaborating Clinics (SLICC) improved the 
ACR criteria, specifying 17 clinical and immunologi-
cal features [16, 22].
The diagnosis of LE should be based on patient 
history, clinical examination, laboratory studies, se-
rology as well as histology. The cutaneous forms of 
LE can be diagnosed by lesional biopsy and followed 
by a lupus band test. They also require profound 
analysis of clinical features [16].
In our previous studies, we found that the mast 
cell counts in renal interstitium differ in the classes 
of SLE and despite the similar pattern of pathological 
changes in the renal glomerulus in lupus nephritis 
class IV and membranoproliferative glomerulone-
phritis, the quantity of mast cells in these two dis-
eases is different. Moreover, we confirmed that mast 
cells contribute to renal tubulointerstitial fibrosis, 
while the number of mast cells correlates with the 
renal interstitial volume (RIV) [23, 24]. 
In this study, we examined the chymase- and 
tryptase-positive mast cell numbers in skin biopsies 
from patients with SLE, DLE and SCLE. We found 
a statistically significant difference in the number of 
mast cells in these three groups. The highest num-
ber of mast cells was in SCLE, lower in DLE and the 
lowest in SLE. These findings suggest that the higher 
number of mast cells in the cutaneous types of LE, 
especially in the subacute type, may be related to the 
formation of the skin lesions. Despite the fact that 
more abundant inflammation is seen in DLE rath-
er than in SCLE, the higher number of mast cells in 
SCLE may be related to the epidermal exocytosis of 
lymphocytes, which can be recruited by MCs [15]. 
Moreover, the higher number of tryptase-positive 
rather than chymase-positive mast cells in all kinds 
of LE may be associated with the partial inactivation 
Fig. 3. Number of chymase positive cells in systemic lupus 
erythematosu (SLE), discoid lupus erythematosus (DLE) 
and subacute cutaneous lupus erythematosus (SCLE). Cen-
tral point – Median; Box 25-75%; Whiskers – Min-Max
Fig. 4. Number of tryptase positive cells systemic lupus er-
ythematosu (SLE), discoid lupus erythematosus (DLE) and 
subacute cutaneous lupus erythematosus (SCLE). Central 
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of chymase in many skin diseases [10]. Our findings 
show that the number of mast cells varies depend-
ing on the biopsy location. The lowest number of 
MCs was noted in the samples taken from the limb 
or trunk; it was higher on the scalp and the highest 
in the biopsies collected from the face. This fact may 
be related to the higher UV exposure of those areas.
There are only a few studies about mast cell quan-
tification in the skin biopsies from patients with CLE 
or SLE; none of them include examination of mast 
cell protease expression. Van Nguyen et al. examined 
the quantification of mast cells in skin of patients 
with CLE after UV radiation; the number of MCs 
was significantly higher. These findings suggest that 
mast cells might play a role in the skin inflammation 
in CLE due to immune cell recruitment and metallo-
proteinase production [11]. In our study, the number 
of mast cells from the biopsies collected from sun-ex-
posed areas was higher too. Martins et al. counted the 
mast cells in skin from patients with cutaneous muci-
nosis; one of the subgroups was mucinosis associated 
with LE. They observed an increase in MC number in 
the skin of patients with cutaneous mucinosis com-
pared with the control group; however, there was 
no significant difference in the number of mast cells 
between the subgroups of cutaneous mucinosis [25]. 
Patel et al. in their study quantified the mast cells in 
five dermatoses: lichen simplex chronicus, psoriasis, 
lichen planus, lupus, and insect bite/allergic contact 
dermatitis/nummular dermatitis with two methods 
of staining: CD117 and toluidine blue. The study 
showed that the mast cell distribution pattern was 
different in the two methods of staining [8]. Naik et 
al. studied non-neoplastic skin lesions for mast cells. 
The MC number in lupus vulgaris was lower than 
in bullous pemphigoid, viral infections of the skin, 
leprosy or dermatitis but higher than in congenital 
diseases [26].
In conclusion, we examined, for the first time, 
the chymase- and tryptase-positive mast cell counts 
within skin biopsies from patients with SLE, DLE 
and SCLE. We found that mast cell numbers differ 
between these groups. The highest count occurs in 
SCLE, a lower one in DLE and the lowest in SLE. 
However, the matter should be investigated further 
with a larger group of patients.
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